Allscripts (MDRX) PT Raised to $15 at Piper Jaffray

Piper Jaffray analyst Sean Wieland reiterated a Neutral rating but bumped his price target on Allscripts (NASDAQ: MDRX) to $15.00 (from $12.00) following record bookings driven by OptumCare win.

Wieland commented, "Allscripts beat bookings with the announcement of a win at OptumCare, a division of OptumHealth, and is the largest ambulatory deal in the company's History. With this deal in the bag, it was a very solid quarter. We are sticking with our 20x target multiple, however rolling it forward to 2017 estimates, and raising our price target to $15."

For an analyst ratings summary and ratings history on Allscripts click here. For more ratings news on Allscripts click here.

Shares of Allscripts closed at $14.27 yesterday.

You May Also Be Interested In

• Merck (MRK) PT Raised to $143 at Truist Securities
• Teradyne (TER) PT Raised to $125 at TD Cowen
• First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen